References
- LeeDMWeinblattMERheumatoid arthritisLancet20013589285 903 91111567728
- Alonso-RuizAPijoanJIAnsuateguiEUrkaregiACalabozoMQuintanaATumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safetyBMC Musculoskelet Disord20089 5218419803
- StrehblowCHaberhauerGFaschingPComparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapyWien Med Wochenschr20101609–10 225 22920632150
- DemoruelleMKDeaneKDTreatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritisCurr Rheumatol Rep2012145 472 48022773387
- van der Helm-van MilAHBreedveldFCHuizingaTWAspects of early arthritis. Definition of disease activity states in early arthritis: remission versus minimal disease activityArthritis Res Ther20068 21616879719
- BurskaABoissinotMPonchelFCytokines as biomarkers in rheumatoid arthritisMediators Inflamm20142014 54549324733962
- VenkateshaSHDudicsSAcharyaBMoudgilKDCytokine-modulating strategies and newer cytokine targets for arthritis therapyInt J Mol Sci2015161 887 906
- MiglioreABallantiELaganàBMartinLSFredianiBBiologic agents for rheumatoid arthritis: can we hypothesize new strategies of treatment?Med Hypotheses2014821 117 12124321737
- RobertiMLRicottiniLCapponiAImmunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgarisJ Biol Regul Homeost Agents2014281 133 13924750799
- Schulze-KoopsHKaldenJRThe balance of Th1/Th2 cytokines in rheumatoid arthritisBest Pract Res Clin Rheumatol2001155 677 69111812015
- RobertsCADickinsonAKTaamsLSThe interplay between monocytes/macrophages and CD4(+) T cell subsets in rheumatoid arthritisFront Immunol20156 57126635790
- RadiceEBelloneGMirandaVEnhancement of the immunostimulatory functions of ex vivo-generated dendritic cells from early-stage colon cancer patients by consecutive exposure to low doses of sequential-kinetic-activated IL-4 and IL-12. A preliminary studyTransl Oncol201584 327 33826310379
- RadiceEMirandaVBelloneGLow-doses of sequential-kinetic- activated interferon-γ enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary studyInt Immunopharmacol2014191 66 7324369312
- GariboldiSPalazzoMZanobbioLLow dose oral administration of cytokines for treatment of allergic asthmaPulm Pharmacol Ther2009226 497 51019464382
- AletahaDNeogiTSilmanAJ2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnn Rheum Dis2010699 1580 158820699241
- LottiTHercogovaJFabriziGAdvances in the treatment options for vitiligo: activated low-dose cytokines-based therapyExpert Opin Pharmacother20151616 2485 249626372794
- ZwerinaJHayerSTohidast-AkradMSingle and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced ArthritisArthritis Rheum200450 277 29014730626
- AlzabinSAbrahamSMTaherTEIncomplete response of inflammatory arthritis to TNFa blockade is associated with the Th17 pathwayAnn Rheum Dis201271 1741 174822550316
- GenoveseMCCohenSMorelandLCombination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexateArthritis Rheum200450 1412 141915146410
- WeinblattMCombeBCovucciASafety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled studyArthritis Rheum200654 2807 281616947384
- GreenwaldMWShergyWJKaineJLEvaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trialArthritis Rheum2011633 622 63221360491